Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tezosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.80 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tezosentan SCHEMBL4524 | 1.00 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL387772 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL1230886 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL6963555 | 0.99 | EDNRA (0.79) | EDNRAEDNRB | |
| SCHEMBL7503358 | 0.93 | EDNRA (0.69) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29379450 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 0.92 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.91 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.91 | EDNRA (0.78) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005876-A | SiRNA for inhibiting expression of angiotensinogen and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-117295520-A | Treatment of ocular diseases using endothelin receptor antagonists | 珀弗斯治疗股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12611126-B2 | Sensors for continuous analyte monitoring, and related methods | DEXCOM, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4721659-A2 | ZWITTERION SURFACE MODIFICATIONS FOR CONTINUOUS SENSORS | DexCom, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4344632-B1 | ZWITTERION SURFACE MODIFICATIONS FOR CONTINUOUS SENSORS | DEXCOM INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12560570-B2 | Diffusion resistance layer for analyte sensors | DEXCOM, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260009759-A1 | ANALYTE SENSOR | DEXCOM, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4642326-A1 | DEVICES AND METHODS FOR SENSING ANALYTES AND DELIVERING THERAPEUTIC AGENTS | Dexcom, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250327768-A1 | ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS | DEXCOM, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20220257700-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | ENB THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220214300-A1 | MEMBRANE LAYERS FOR ANALYTE SENSORS | DEXCOM, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3999062-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | ENB Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11338014-B2 | Methods and compositions for treatment of endothelin B receptor expressing tumors | ENB THERAPEUTICS, INC. | 2022-05-24 | — | — | US | disclosed |
| US-20220142532-A1 | POLYMER MEMBRANES FOR CONTINUOUS ANALYTE SENSORS | DEXCOM, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-114423425-A | Treatment of urothelial and renal cancers by using endothelin B receptor antagonists | ENB治疗公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220071530-A1 | POLYMER MEMBRANES FOR CONTINUOUS ANALYTE SENSORS | DEXCOM, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11262326-B2 | Membrane layers for analyte sensors | DEXCOM, INC. (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115251-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-11338014-B2 | Methods and compositions for treatment of endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-20250327768-A1 | ENZYME IMMOBILIZED ADHESIVE LAYER FOR ANALYTE SENSORS | MGAM, IDUA, UNG | EDNRA 3414/4885EDNRB 4273/4885 |
| US-12533390-B2 | Methods and compositions for treatment of Endothelin B receptor expressing tumors | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-20220257700-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS | EDNRB, EDNRA, CASP8 | EDNRA 2/4885EDNRB 1/4885 |
| US-12560570-B2 | Diffusion resistance layer for analyte sensors | MGAM, PGM2, CUTA | EDNRA 4034/4885EDNRB 4111/4885 |
| US-12611126-B2 | Sensors for continuous analyte monitoring, and related methods | CUTA, CD69, PIEZO1 | EDNRA 1122/4885EDNRB 2130/4885 |
| US-11262326-B2 | Membrane layers for analyte sensors | MGAM, UGDH, UNG | EDNRA 4482/4885EDNRB 4723/4885 |
| US-20220265628-A1 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS | EDNRB, EDNRA, UTS2R | EDNRA 2/4885EDNRB 1/4885 |
| US-20260009759-A1 | ANALYTE SENSOR | EPCAM, SLC6A12, GJB2 | EDNRA 2514/4885EDNRB 3134/4885 |
| US-20220214300-A1 | MEMBRANE LAYERS FOR ANALYTE SENSORS | MGAM, UGDH, UNG | EDNRA 4482/4885EDNRB 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.